US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
REGULATED INFORMATION
GHENT, Belgium, Jan. 21, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 288,170 common shares have been issued by the Company in exchange for €1,192,292.70 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has 55,100,544 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,528,657 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has approximately 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media relations Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: [email protected]
Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: [email protected]
Pdf version of the press release http://hugin.info/137912/R/1980185/725377.pdf
HUG#1980185
